Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...

Atea Pharmaceuticals Inc (AVIR) showcases strong clinical progress and financial stability while navigating competitive challenges in the HCV treatment landscape.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

Among rural people with chronic HCV infection and a history of injection drug use, a mobile telemedicine-based intervention vs enhanced usual care improves treatment initiation and cure rates.

A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.